The bottom line: Jetstream Venture Fund has added Rejuvenation Technologies to its portfolio, backing a preclinical platform that uses targeted lipid nanoparticles to deliver temporary telomerase mRNA. The investment adds validation and capital to an ambitious idea. It does not show that the technology is safe, effective or capable of rejuvenating people.
What was announced
Jetstream disclosed the investment on September 16. It did not publish the size, price or ownership terms of the transaction. Rejuvenation Technologies had previously raised a $10.6 million seed round led by Khosla Ventures, with participation from Y Combinator and other investors.
According to company materials cited by Jetstream, Rejuvenation has raised about $16 million in venture funding and more than $8 million in grants. Those figures are company-reported and should not be treated as audited financial disclosure.
The company is developing three named preclinical programs: TeloAT2 for pulmonary fibrosis, TeloHep for chronic liver disease and TeloHSC for hematologic conditions. Its website lists Phase 1 studies as planned in Australia, but no human efficacy result has been reported.
What the platform is trying to do
Telomeres are repetitive DNA structures at the ends of chromosomes. They help protect chromosome ends when cells divide. In many human cells, telomeres shorten over repeated divisions. When they become critically short or dysfunctional, cells can stop dividing, enter senescence or die.
Telomerase can add sequence back to telomeres. Rejuvenation Technologies packages modified messenger RNA encoding telomerase reverse transcriptase, or TERT, inside lipid nanoparticles. Once delivered to a target cell, the mRNA is intended to produce telomerase for a limited period. The mRNA and protein then degrade.
The approach combines two bets. One is that temporary telomerase activity can restore useful replicative capacity without the risks of permanent activation. The other is that the nanoparticles can deliver the message to the right tissue and cell type while limiting exposure elsewhere.
Why targeting and timing matter
Telomerase is biologically powerful and therefore difficult to use safely. Most cancers reactivate telomerase or another telomere-maintenance pathway, allowing malignant cells to keep dividing. That does not mean a brief dose of TERT mRNA causes cancer, but it explains why duration, dose, tissue targeting and long-term monitoring are central questions.
mRNA offers a reversible instruction rather than a permanent DNA edit. Lipid nanoparticles may also be engineered to favor particular organs. The company’s lung program, for example, uses a lung-targeting particle intended to reach cells involved in short-telomere pulmonary fibrosis. The liver program uses a different delivery strategy.
Temporary does not automatically mean safe, and targeted does not mean perfectly specific. Researchers will need to measure where the particles travel, which cells produce TERT, how long the effect lasts, whether telomeres lengthen uniformly and whether damaged or precancerous cells gain an unwanted growth advantage.
Why investors are interested
The platform sits at the intersection of three active areas: mRNA medicines, tissue-targeted delivery and diseases linked to telomere dysfunction. If the delivery system can be retuned for different organs, one technical platform could support several drug programs.
There is also external non-dilutive support. The California Institute for Regenerative Medicine awarded $3.98 million to advance nucleoside-modified TERT mRNA in a lung-targeting lipid nanoparticle for short-telomere-related pulmonary fibrosis. In July 2026, the National Institutes of Health awarded about $2.06 million for work intended to move a liver-directed program toward an Investigational New Drug submission. The project includes manufacturing, genotoxicity and non-human-primate toxicology work.
Those grants matter because they fund specific development steps and subject proposals to outside review. They are not endorsements that the therapy will work in patients.
What evidence exists so far
The foundational work came from Stanford researchers, including Rejuvenation co-founder John Ramunas. A 2015 study reported that transient delivery of modified TERT mRNA lengthened telomeres in cultured human cells and increased their proliferative capacity. The effect was temporary, and cells later returned to their usual pattern of telomere shortening.
Rejuvenation and its investors describe preclinical animal and non-human-primate data, regulatory discussions and a substantial patent portfolio. Detailed results for the current therapeutic candidates have not yet been published in a form that allows independent evaluation of efficacy and safety across doses.
What would move the story forward
The first requirement is a transparent preclinical package. That should include biodistribution, dose response, duration of TERT expression, telomere-length measurements, tissue repair outcomes, immune reactions, genotoxicity and tumor surveillance. Results should be reported for the final clinical formulation, not only earlier laboratory versions.
A first-in-human trial would initially be expected to emphasize safety, tolerability, pharmacology and evidence that the therapy reaches its intended cells. Even a successful early trial would not show that telomere extension slows whole-body aging or extends human lifespan.
The most credible near-term path is disease-specific. Patients with defined telomere dysfunction and serious lung, liver or blood disorders may offer a clearer biological rationale and measurable clinical outcomes than a broad claim about rejuvenation.
The Lifespan Brief assessment
Jetstream’s investment is a meaningful financing event for Rejuvenation Technologies, particularly alongside government grants aimed at clinical translation. The platform is scientifically plausible and addresses an important delivery problem.
It remains a high-risk, preclinical biotechnology program. Funding, patents and regulatory meetings can help a company reach the experiments that matter. They cannot substitute for those experiments. The decisive evidence will come from independently interpretable preclinical results and carefully monitored human trials.
Sources
- Jetstream Invests in Rejuvenation Technologies, Jetstream Venture Fund, September 16, 2026.
- Advancing a telomere extension biologic to treat alcohol-associated liver damage to IND, NIH RePORTER.
- Telomerase mRNA for short telomere related pulmonary fibrosis, California Institute for Regenerative Medicine.
This article is for general information and is not investment or medical advice.